Bioventus Inc. Stock Price, News & Analysis

Bioventus (Nasdaq: BVS) has secured a new $400 million Senior Secured Credit Agreement, comprising a $300 million term loan and a $100 million revolving credit facility, maturing on July 31, 2030. The agreement represents significant improvements over their 2019 Credit Agreement, featuring a 75 basis point reduction in interest margin, generating over $2 million in annual interest savings.

Key enhancements include an increase in revolving credit facility from $40 million to $100 million, and a reduction in annual term loan amortization from 10% to 5%. The company used the proceeds to repay its outstanding $333 million loan balance under the 2019 agreement, utilizing the new term loan, $30 million from the revolving facility, and $3 million cash on hand.

Bioventus (Nasdaq: BVS) has received FDA 510(k) clearances for two new Peripheral Nerve Stimulation (PNS) products: TalisMann™ and StimTrial™. These innovative solutions target the rapidly growing PNS market, which is projected to exceed $500 million by 2029 with over 20% annual growth.

TalisMann™ combines electric field conduction technology with an integrated pulse generator for treating chronic nerve pain, while StimTrial™ enables physicians to evaluate patient response to PNS therapy. The company plans a limited commercial release in Q3 2025, followed by a broader rollout in early 2026.

Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has scheduled its second quarter fiscal year 2025 earnings release and conference call. The company will announce its financial results before market open on Wednesday, August 6, 2025, followed by a management-hosted conference call at 8:30 a.m. Eastern Time.

Investors can participate by dialing 1-800-715-9871 (Conference ID: 1859022) or accessing the webcast through the company's investor relations website. The webcast recording will remain available for replay until August 5, 2026.

[]

Bioventus (BVS) reported Q1 2025 financial results with revenue of $123.9 million, showing a 4.3% decline from the prior year, while organic revenue grew 5.0%. The company's net loss improved to $0.04 per share from $0.08 in the prior year, with non-GAAP earnings increasing 33% to $0.08 per share. Pain Treatments revenue grew 3.9% to $58.9M, Surgical Solutions increased 7.0% to $45.2M, while Restorative Therapies declined 35.3% to $19.7M due to the Advanced Rehabilitation business divestiture. The company maintained its 2025 guidance, projecting revenue of $560-570M, Adjusted EBITDA of $112-116M, and Non-GAAP EPS of $0.64-0.68.

Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has scheduled its first quarter fiscal year 2025 financial results announcement for May 6, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time on the same day, where management will discuss the results and provide a business update.

Investors can participate by dialing 1-833-636-0497 and referencing the Bioventus Conference Call. A live webcast and accompanying materials will be available on the company's investor relations website, with replay access until May 5, 2026.

Bioventus (BVS) reported strong Q4 2024 results with revenue reaching $153.6 million, up 13.5% year-over-year, driven by double-digit growth in Pain Treatments and Surgical Solutions. The company reduced its net loss from continuing operations to $0.3 million, compared to $7.7 million in the prior year.

Full-year 2024 revenue totaled $573.3 million, representing an 11.9% increase, with organic growth of 14.4%. Adjusted EBITDA from continuing operations grew 22.5% to $108.9 million. The company successfully divested its Advanced Rehabilitation Business for $24.7 million and reduced long-term debt by $48.3 million in Q4.

Looking ahead, Bioventus projects 2025 revenue between $560-570 million, representing organic growth of 6.1-8.0%, and expects Adjusted EBITDA of $112-116 million with improved margins.

Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has scheduled its fourth quarter fiscal year 2024 financial results announcement for March 11, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time on the same day, featuring management discussion of results and business updates.

Investors can participate by dialing 1-833-636-0497 and referring to the Bioventus Conference Call. A live webcast and accompanying materials will be available on the company's investor relations website, with replay access until March 10, 2026.

Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, announced that its CEO, Rob Claypoole, will present at the 43rd Annual J.P. Morgan Healthcare Conference.

The presentation is scheduled for Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). A live webcast, including a Q&A session, will be accessible on the Investors section of the Bioventus website. This webcast will be available until February 15, 2025.

Bioventus (BVS) has completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners, a private equity firm specializing in HealthTech companies. The transaction, which was initially announced on October 1, 2024, has generated approximately $20 million in net closing proceeds for Bioventus, enhancing the company's liquidity position. This strategic move allows Bioventus to sharpen its focus and improve execution within its core business segments.